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ABSTRACT
Through whole-transcriptome profiling of HER2+ breast carcinomas (BCs), we previously showed that
those sensitive to trastuzumab are addicted to this oncoprotein and are enriched in immune pathways,
raising the hypothesis that HER2 itself regulates immune cell recruitment. In the present study we
investigated the relationship between HER2 activity and the pro-trastuzumab tumor immune milieu.
Gene expression profiling and immunohistochemistry analysis of 53 HER2+ BCs showed that trastuzu-
mab-sensitive tumors expressed significantly higher levels of chemokines involved in immune cell
recruitment, with higher infiltration of T cells and monocytes, and higher levels of PD-1 ligands than
tumors that do not benefit from trastuzumab. In vitro analysis in HER2+ BC cells revealed that CCL2
production was induced by HER2 stimulation with EGF/HRG via the PI3K-NF-kB axis, and down-modu-
lated by HER2 inhibition with trastuzumab. CCL2 expression was higher in HER2+/ER− than HER2+/ER
+ BC cell lines, and degradation of ER by fulvestrant induced an enhancement in NF-κB transcriptional
activity and consequent CCL2 expression. Trastuzumab efficacy relied on CCL2 levels and monocytes
present in the tumor microenvironment in FVB mice bearing HER2+ mammary carcinoma cells. HER2
signals were also found to sustain the expression of PD-1 ligands in tumor cells via the MEK pathway.
Overall, our results support the concept that the activated HER2 oncogene regulates recruitment and
activation of tumor infiltrating immune cells and trastuzumab activity by inducing CCL2 and PD-1
ligands and that ER activity negatively controls the HER2-driven pro-trastuzumab tumor
microenvironment.
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The clinical benefit of the monoclonal antibody trastuzumab
has been widely demonstrated in HER2+ patients with breast
carcinoma (BC); however, a considerable number of women
do not benefit from this therapy.1,2 Several studies have
investigated the possibility of identifying biomarkers to dis-
tinguish patients sensitive to this therapy from those suited
for novel targeted approaches.3 Recently, analyses of gene
expression profiles of tumor blocks from patients enrolled in
clinical trials support a relationship between tumor depen-
dence on HER2 signaling (HER2-E by PAM50) and trastuzu-
mab sensitivity.4,5 Moreover, based on increasing evidence of
the role of both innate and adaptive immunity in trastuzumab
mechanism of action,6,7 immune-related information such as
tumor infiltrating lymphocyte count or immune-related sig-
natures were explored and found to be predictive of trastuzu-
mab benefit in several studies.8 In this context, through
transcriptome profiling of archival formalin-fixed paraffin
embedded (FFPE) tumor blocks from HER2+ cases treated
with adjuvant trastuzumab in our Institute during routine
clinical practice,9 we identified BCs exquisitely sensitive to
treatment as those with both tumor dependence on HER2
signaling by PAM50 classification, as well as enriched in
immune genes,9 supporting the predictive power of both
addiction to HER2 signaling and immune infiltration because
of their ability to identify the same tumors. Thus, as described
for some oncogenes that cause pathogenesis of human cancer
(e.g., RAS, BRAF, RET/PTC1, and MYC),10 a direct connec-
tion between HER2 activity and tumor immune infiltration
may occur.
In the present study, we investigated whether a relationship
exists between HER2 activity and immune infiltration and the
means by which HER2 signaling contributes to mold the tumor
immune microenvironment to further trastuzumab anti-tumor
activity. We found that trastuzumab-sensitive tumors express
significantly higher levels of chemokines involved in immune
cell recruitment than tumors that do not benefit from trastuzu-
mab. In vitro analysis inHER2+ BC cell lines revealed that CCL2,
mainly involved in the recruitment of monocytes, was
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modulated by the PI3K/NF-kB pathway downstream of the
HER2 receptor. Trastuzumab efficacy was dependent on CCL2
levels and monocytes present in the tumor microenvironment
(TME) in an in vivo model. Moreover, estrogen receptor was
found to block the HER2-mediated production of CCL2 in vitro
by inhibiting NF-kB activity, suggesting that the recruitment of
immune cells relevant for trastuzumab anti tumor activity may
be ascribed to intersecting signals between HER2 and the ER.
Results
Association between HER2 dependency and the immune
microenvironment in human HER2+ BCs
We recently developed a TRAstuzumab Risk model (TRAR)
predictive of trastuzumab benefit both in adjuvant and neoad-
juvant settings.9 Through gene expression analysis of 53
HER2+ BCs of the Group Herceptin in Adjuvant Therapy
(GHEA) cohort we identified responsive tumors (TRAR-
low) as those dependent on HER2 signals (HER2-E by
PAM50 classification), enriched in immune genes, and highly
infiltrated by CD8+ T cells.9 Confirming the tumor depen-
dence on HER2 signal, TRAR-low tumors exhibited lower
levels of the estrogen receptor-related score (ERS), indicative
of activity of the ER pathway,11 than TRAR-high tumors
(Figure 1A).
To investigate whether a causal relationship exists
between HER2 oncogene activity and tumor immune infil-
tration, in the present study the expression levels of
chemokines involved in the recruitment of immune cells
were explored in the GHEA cohort. Mean expression of all
chemokine genes belonging to the CXC and CC subfami-
lies (Supplementary Table S1) was significantly higher in
tumors classified as low risk of relapse after trastuzumab
treatment (TRAR-low) than in high risk tumors (TRAR-
high) (p < 0.05) (Figure 1B). Moreover, TRAR-low tumors
showed significantly higher levels of CC subfamily chemo-
kines (CCL2, CCL5, CCL8, CCL11, and CCL22), mainly
involved in the recruitment of monocytes to the site of
inflammation, and of CXC subfamily chemokines (CXCL9,
CXCL 10, CXCL 11, and CXCL 13) that induce the migra-
tion mainly of T cells and B cells12 (Figure 1C and
Supplementary Table S2). IHC analysis of CXCL9,
CXCL10, and CCL2 in FFPE specimens of the same
cases from the GHEA cohort showed chemokine expres-
sion mainly in tumor cells and significant association with
TRAR-low classification (Figure 1D). CCL2 was found to
also be expressed in stromal cells with macrophage mor-
phology, as indicated by arrows in Figure 1D, CCL2 panel.
As a possible consequence of high expression of these
chemokines, TRAR-low tumors exhibited higher infiltra-
tion of CD8+ T cells, as previously described,9 and mono-
cytes (CD68+ cells) than TRAR-high tumors (p = 0.0063)
(Figure 2A). CD68+ cells were mainly localized in tumor
stroma and exhibited similar levels of contact with tumor
cells in some areas in both TRAR-low and TRAR-high
tumors. Similar staining patterns were observed by using
both the anti-CD68 clone KP1 and PGM1, the latter
Figure 1. Enhanced expression of chemokines in HER2+ BCs classified as sensitive to trastuzumab. A) ERS score expression in GHEA tumors according to TRAR
classification. p-value by unpaired t-test. B) Average expression of chemokine genes in GHEA tumors. p-value by unpaired t-test. C) Chemokine genes significantly
and differentially expressed in TRAR-low vs TRAR-high tumors. For each gene, the fold difference (FC) between the two groups and the relative p-value are reported.
D) Representative images of CXCL9, CXCL10, and CCL2 positive tumors. Arrows show CCL2-positive macrophages. Scale bars: 50 μm in the main images and 20 μm in
the zoomed images. Lower panels show the percentages of positive cases (white boxes) and negative cases (grey boxes) according to TRAR classification. p-values by
Fisher’s test (n = 51).
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described to be more specific for macrophages than the
anti-CD68 KP1. ssGSEA analysis showed an enrichment in
M1 gene patterns in TRAR-low vs TRAR-high tumors,
whereas no differences in genes related to M2 polarization
were found (Supplementary Fig. S1). No differences in the
number of regulatory T cells or CD33+ cells as defined
according to TRAR classification were detected
(Figure 2B).
Based on i) the higher infiltration of effector immune cells in
TRAR-low than TRAR-high tumors without concomitant
increase of immune suppressive cells, ii) the poor prognosis of
TRAR-low patients when not treated with trastuzumab9, and iii)
the emerging data showing that PD-L1 expression by tumor cells
could block lymphocyte activity,13 we analyzed PD-1 ligand
expression according to TRAR classification. PD-L1 and PD-L2
were expressed at significantly higher levels in TRAR-low than
TRAR-high tumors at the mRNA level (Figure 2C). Accordingly,
higher PD-L1 and PD-L2 protein expression was observed in
tumor cells by IHC in TRAR-low compared to TRAR-high
tumor samples (Figure 2D), supporting the possibility that these
tumors escape the control of the recruited immune cells through
the PD-1 receptor-ligand axis.
These data indicate that HER2+ BCs classified as sensitive
to trastuzumab (TRAR-low) comprised those enriched in the
expression of chemokines along with specifically recruited
immune cells, and expressing PD-1 ligands as an immune
escape mechanism.
Regulation of chemokine expression by HER2-mediated
signaling
To understand whether CXC and CC chemokines enriched
in TRAR-low tumors could be regulated by HER2 signals,
HER2+ BC cells (BT474, SKBr3, and ZR75.30) were treated
with EGF/HRG or trastuzumab, in order to activate signals
downstream of HER2/EGFR and HER2/HER3 heterodimers
or to block the receptor signaling, respectively
(Supplementary Fig. S2) and analyzed by qRT-PCR for
chemokine expression. Treatment with EGF or HRG did
not induce up-modulation of CXCLs, or CCL5 expression
(Figure 3A,B) nor was down-modulation revealed upon
inhibition of HER2 signaling by trastuzumab treatment
(Figure 3C). CCL22 was increased by EGF or HRG whereas
no reduction upon inhibition of HER2 by trastuzumab was
observed, suggesting no direct involvement of HER2-
mediated signaling in regulating the expression of this
chemokine. In contrast, CCL2 always showed significant
up- or down-modulation associated with HER2 activity or
inhibition, respectively (Figure 3A-C). CCL2 protein quan-
tification by ELISA in culture supernatants of BT474 and
Figure 2. Characterization of immune TME of HER2+ BCs. A-B) IHC evaluation of CD68+ cells (A), FOXP3+ Treg, and CD33+ cells (B) in tissues of the GHEA cohort. The
average number of positive cells in three-fields is shown. Scale bars: 50 μm in the main images and 20 μm in the zoomed images. p-value by unpaired t-test (n = 47)
C) PDL1 and PDL2 mRNA expression in tumors of the GHEA cohort according to TRAR classification. p-values by unpaired t-test. D) Representative image of PD-L1
and PD-L2 positive tumors. Scale bars: 50 μm and 20 μm in the zoomed image. Lower panel shows the percentages of negative cases (grey boxes) and positive cases
(white boxes) according to TRAR classification. p-values by Fisher’s test (PD-L1: n = 51, PD-L2: n = 25).
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SKBr3 cells confirmed an increased release of this chemo-
kine in both cell lines after treatment with EGF/HRG com-
pared to untreated cells (Figure 3D). In support of the role
of HER2 signaling in modulating CCL2 production by
tumor cells, CCL2 mRNA was found to be significantly
reduced by approximately 40% (± 18%) in 70% of tumor
biopsies of the 03–311 trial14 after treatment with one cycle
of trastuzumab alone (Figure 3E). In addition, immuno-
fluorescence evaluation of HER2 and CCL2 in murine
mammary carcinomas derived from human d16HER2 FVB
transgenic mice15 showed co-expression of CCL2 with the
HER2 oncogene in tumor cells (Figure 3F).
In vitro changes of CXCL expression levels observed upon
stimulation or blockage of ERBB2 receptor signaling mutually
associated with ERBB2 mRNA modulation with a significant
positive correlation between CXCL9, CXCL CXCL 11, and
CXCL 13 and ERBB2 levels (Supplementary Fig. S3A).
Moreover, HER2 mRNA levels directly and significantly corre-
lated withCXCL9,CXCL 10, andCXCL 13 levels in tumors of the
GHEA cohort (Supplementary Fig. S3B), suggesting the possible
co-expression of these genes in tumor cells rather than the
regulation of their expression by HER2.
Involvement of CCL2 expression in trastuzumab activity
To investigate the relevance of CCL2 production and monocyte
recruitment by tumor cells in trastuzumab efficacy, FVB mice
bearing human HER2+ mammary carcinoma cells (MI6) were
treated with trastuzumab with or without a CCL2 blocking
monoclonal antibody (aCCL2) that can reportedly raise circulat-
ing total CCL2.15,16 CCL2 plasma level was 10-fold higher in
animals receiving blocking antibody than in untreated mice
(Figure 4A), and in vitro recruitment of splenocytes by plasma
of animals treated with aCCL2 compared to untreated was
improved (Supplementary Fig. S4E). Based on these data, we
analyzed whether the increment in CCL2mirrored an increment
in immune cells in the TME; accordingly, we observed an
increase in the percentage of CD45+ cells in tumors treated
Figure 3. Changes of chemokine expression levels upon stimulation or blockage of HER2 receptor signaling. A-C) Chemokine mRNA expression in cells as evaluated
by qRT-PCR after 6-h treatment with EGF (A), HRG (B), and trastuzumab (C). Data are expressed as fold to untreated cells (dotted lines) and refer to independent
experiments in BT474 (●), ZR75.30 (▲), and SKBr3 (■). D) CCL2 release upon stimulation with 20 ng/ml EGF and HRG for 24 h in BT474 (●) and SKBr3 (■) as
evaluated by ELISA. Data are expressed as fold to untreated cells (dotted line) and refer to independent experiments. E) CCL2 gene expression in 50 HER2+ BC
biopsies belonging to the GSE70360 dataset obtained before (pre) and after (post) treatment with one cycle of trastuzumab alone. p-value by paired t-test. F)
Representative expression of HER2 and CCL2 in tumors derived from d16HER2 transgenic mice as evaluated by immunofluorescence. Scale bars: 10 μm. Right panel
shows quantification of CCL2 positivity in HER2-positive and HER2-negative areas. Data are the means ± SD (n = 12). p-value by unpaired t-test.
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with aCCL2 compared to untreated cells (Figure 4B) that was
reflected in an increase in the number of monocytes/macro-
phages (CD11b+ F4/80+) (Figure 4C), T (CD3+) (Figure 4D),
and NK (CD3− CD49b+) (Figure 4E) cells. Notably, treatment
with anti CCL2 antibody resulted in a significantly improved
trastuzumab inhibitory activity (Figure 4F). In addition, a sig-
nificant positive correlation was found between circulating levels
of CCL2 and immune cells within the TME (CD45+: r = 0.84,
p = 0.0021; F4/80+: r = 0.79, p = 0.0065; CD3+: r = 0.91,
p = 0.0002; CD49b+: r = 0.93, p = 0.0001; Supplementary
Fig. S4A- B) in mice treated with or without aCCL2. Moreover,
a direct correlation between circulating levels of CCL2 and
tumor infiltrating CD11b+ F4/80+ cells was observed in animals
treated with trastuzumab (r = 0.72, p = 0.0292), as well as a trend
toward a positive correlation (r = 0.56, p = 0.0958) between the
percentage of tumor growth inhibition induced by trastuzumab
and the number of these cells (Supplementary Fig. S4C-D). Even
though chemokine(s) other that CCL2 might have been
increased upon treatment with aCCL2 and may take part in
monocyte recruitment, these results strongly suggested that the
efficacy of trastuzumab relies on CCL2 levels and monocytes
present in the TME.
Regulation of CCL2 expression by HER2-downstream
signals
To explore which HER2-mediated signal(s) was responsible
for CCL2 expression, we focused on the RAS-MAPK and
PI3K-AKT pathways, based on their known activation upon
treatment with EGF and HRG, by treating SKBr3 and BT474
cells with MEK (UO126) or PI3K (LY294002) inhibitors
(MEKi and PI3Ki). The activation of these pathways by
EGF/HRG in our models and the activity of MEKi, PI3Ki,
with respect to inhibiting the activation of target molecules
were confirmed by western blot (WB) analysis of cell lysates
obtained from treated cells (Supplementary Fig. S5). PI3Ki in
SKBr3 upon treatment with EGF/HRG induced a reduction in
CCL2 expression at both the mRNA and protein level
Figure 4. Correlation between CCL2 levels, monocyte infiltration in the TME, and trastuzumab activity. A) CCL2 protein quantification by ELISA in serum derived from
FVB mice with MI6 tumors treated with or without a CCL2 blocking antibody (aCCL2) at 200 μg/mouse and/or trastuzumab at 5 mg/kg. p-values by unpaired t-test.
B) Frequency of CD45+ cells in tumors derived from mice treated as in A, as evaluated by flow cytometry. p-values by unpaired t-test. C-E) Number of infiltrating
macrophages (C), T cells (D), and NK cells (E) in FVB mice treated as in A. Shown are the numbers of each immune population calculated for 105 live cells, as
determined by flow cytometry. p-values by unpaired t-test. F) Percentage of tumor growth inhibition by trastuzumab in mice treated with or without aCCL2.
*p < 0.05 **p < 0.01, by unpaired t-test.
Figure 5. CCL2 expression is regulated by HER2 signaling in SKBr3 and BT474 cells. A-B) CCL2 mRNA (A) and protein (B) quantification by qRT-PCR and ELISA,
respectively, in SKBr3 cells treated with EGF or HRG and/or with PI3Ki (LY294002), MEKi (UO126), or NF-kBi (BAY 11–7082) inhibitors for 6 h. C) CCL2 mRNA expression
in BT474 cells treated as in A. Data are expressed as fold to EGF/HRG treated cells (dotted lines) and are representative of at least two experiments. *p < 0.05,
**p < 0.01, ***p < 0.001 by unpaired t-test.
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(Figure 5A and 5B, respectively). Conversely, MEKi induced
up-modulation of CCL2, likely owing to the described activa-
tion of Akt upon continuous blockage of MEK signals,17 as we
also observed in our models (data not shown). Downstream of
the PI3K-AKT pathway, BAY 11–7082, a NF-kB inhibitor,
significantly reduced the CCL2 improvement mediated by
EGF/HRG in SKBr3 cells (Figure 5A-B). These data were
validated in BT474 cells (Figure 5C and Supplementary
Fig. S5), pointing to the role of NF-kB downstream to the
HER2 oncogene in the regulation of CCL2.
Based on i) the described inhibitory crosstalk between NF-
kB and ER signaling,18 ii) the therapeutic activity of trastuzu-
mab mainly in ER− tumors,3 iii) the low activity of ER in
TRAR-low tumors (Figure 1A), and iv) the negative correla-
tion between the activity of ER and CCL2 expression in
tumors of the GHEA cohort (r = −0.36 p = 0.0082), we
investigated whether ER might affect HER2-dependent pro-
duction of CCL2 by inhibiting NF-kB activity. CCL2 expres-
sion was evaluated in HER2+ BC cell lines according to ER
expression. Figure 6A shows the characterization of ER
expression by WB (left panel) and activity, mirrored by pro-
gesterone receptor (PGR) expression as evaluated by qRT-
PCR (right panel). In accordance with the literature,19 a
higher transcriptional activity of NF-kB was observed in ER
− cell lines (HCC1954, SKBr3, and MDAMB453) than ER
+ lines (BT474, MDAMB361, and ZR75.30) (Figure 6B).
Hence, CCL2 mRNA and protein levels were higher in ER−
than ER+ cell lines (Figure 6C). Notably, treatment of ER
+ cells (BT474 and ZR75.30) with fulvestrant, a selective ER
down-regulator that induced down-modulation of ER expres-
sion and activity (Figure 6D and 6E), promoted an increase in
NF-kB transcriptional activity (Figure 6F) and an enhance-
ment of CCL2 expression (Figure 6G and 6H). These results
support a role of ER-HER2 crosstalk in the production of
CCL2 in HER2+ tumors.
Regulation of PD-1 ligand expression by HER2-mediated
signaling
Based on the PD-1 related immune escape mechanism of
TRAR-low tumors (Figure 2C), we hypothesized that HER2
itself modulates the expression of PD-1 ligands in tumor cells
to evade the immune control. HER2+ BC cells with detectable
levels of PD-L1 by qRT-PCR (HCC1954 and SKBr3) were
treated with EGF/HRG and analyzed for PD-1 ligand expres-
sion. EGF treatment induced an up-modulation of PD-L1 and
PD-L2 in both cell lines both at the mRNA (Figure 7A) and
protein level (Figure 7C and Supplementary Fig. S6), whereas
HRG stimulated expression of these ligands, at a lower extent
than EGF, only in SKBr3 cells (Figure 7 and Supplementary
Figure 6. Inhibition of the production of CCL2 in HER2+ tumor cells by ER activity. A) Left panel: WB analysis of pHER2, HER2, and ER; right panel: qRT-PCR
quantification of PGR mRNA in HER2 + BC cell lines maintained in standard medium conditions. All performed independent experiments are shown. B) NF-kB activity
in HER2+ BC cell lines as determined by luciferase assay. All performed independent experiments are shown. C) CCL2 mRNA (left panel) and protein (right panel)
quantification by qRT-PCR and ELISA, respectively, in HER2+ BC cell lines. All performed independent experiments are shown. D) WB analysis of pHER2, HER2, and ER
in BT474 and ZR75.30 treated with or without 100 nM fulvestrant for 24 h. E-H) PGR mRNA quantification by qRT-PCR (E), NF-kB activity by luciferase assay (F), CCL2
mRNA quantification by qRT-PCR (G), and CCL2 protein quantification by ELISA (H) in BT474 and ZR75.30 cells treated with or without fulvestrant as in D. Data are
representative of two experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test.
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Fig. S6), probably because of the very low levels of the HRG
receptor HER3 in HCC1954 cells (Supplementary Fig. S2).
Reduction of HER2 signaling by trastuzumab or lapatinib
was evaluated only in HCC1954 cells owing to their basal
positivity for membrane-associated PD-L1 protein
(Supplementary Fig. S6). HER2 signal inhibition significantly
reduced the expression of PD-L1 and PD-L2 at both the
mRNA and protein level (Figure 7B and 7C, respectively).
Analysis of HCC1954 and SKBr3 cells with or without
MEKi and PI3Ki treatment showed that the up-modulation
of PD-1 ligands upon EGF/HRG treatment was mainly abro-
gated by MEKi (Figure 7D-F). Together, these results support
that HER2 signaling, mainly through EGFR-HER2 heterodi-
merization, sustains expression of PD-1 ligands in tumor cells,
which likely contributes to innate immune resistance.
Discussion
In the present study, we provide evidence for the first time that
activation of the HER2 oncogene induces the tumor cell pro-
duction of CCL2 and the ability of CCL2 to recruit monocytes/
macrophages at the tumor site eventually results in an
improved trastuzumab-immune-mediated anti-tumor activity.
Accordingly, tumors dependent on HER2 signaling and classi-
fied by our TRAR model as responsive to trastuzumab
treatment (TRAR-low) were found to express higher levels of
CCL2 and to be more infiltrated by CD68+ cells than non-
HER2 addicted, trastuzumab resistant (TRAR-high) tumors.
This supports the reported concept that trastuzumab, through
its constant fragment Fc, mediates anti-tumor cytotoxic effects
by rendering tumor cells recognizable by macrophages7,19
other than NK cells. Results obtained in an animal model
using an anti-CCL2 monoclonal antibody, which indicated
improved monocyte/macrophage (CD11b+ F4/80+) infiltra-
tion in the TME associated with higher trastuzumab anti-
tumor inhibitory activity, supported the role of these immune
cells in trastuzumab efficacy. However, we could not exclude
that other CD68+ cells, such as dendritic cells, that are
recruited by CCL220 might also infiltrate these tumors. As
dendritic cells express the Fcγ receptor, they may also contri-
bute to the responsiveness of TRAR-low tumors to trastuzu-
mab by taking up tumor cell fragments opsonized by the
antibody and priming CD4+ or CD8+ T lymphocytes.7
HER2-mediated production of CCL2 was found to be
supported by the PI3K/AKT/NF-kB axis downstream of the
oncogene, as demonstrated by the significant reduction in
CCL2 expression at both the mRNA and protein level
observed in BC cell lines upon treatment with PI3Ki and
NF-kBi. Thus, an abnormal HER2 activation such as that
occurring in tumors with HER2 amplification could generate
Figure 7. Regulation of the expression of PD-1 ligands by HER2 signaling in HCC1954 and SKBr3 cells. A) PDL1 (upper panel) and PDL2 (lower panel) mRNA
expression in HCC1954 and SKBr3 cells treated with EGF or HRG for 6 h. B) PDL1 (upper panel) and PDL2 (lower panel) mRNA expression in HCC1954 cells treated
with trastuzumab (T) or lapatinib (L) for 24 h. Data are the means ± SD of fold increase in treated vs untreated cells (dotted lines) and are representative of two
experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test. C) Relative quantification of membrane-associated PD-L1 expression in HCC1954 (upper panel)
and SKBr3 (lower panel) cells treated as in A and B. Each dot represents an independent experiment and represents the ratio between the percentages of PD-L1
positive cells in treated vs untreated cells (dotted lines). **p < 0.01, ***p < 0.001 by paired t-test D-F) Relative PD-L1 and PD-L2 expression in HCC1954 (D) and SKBr3
(E-F) cells. mRNA quantification in cells treated with EGF (D-E) or HRG (F) and/or with PI3Ki (LY294002) or MEKi (UO126) for 6 h. Data are expressed as fold to EGF/
HRG treated cells and are representative of two experiments. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired t-test.
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an inflammatory environment, as has been described for other
oncogenes such as RET/PTC1 in thyroid cancer,21 RAF in
melanoma, and MYC in pancreatic tumors.22 Considering
that the PI3K/AKT pathway is common to different mem-
brane receptors, tumor cell signals other than HER2 may
contribute to CCL2 expression albeit to a lesser extent in
HER2-addicted BCs. In these tumors, signal derived from
HER2 homodimerization and its heterodimerization with
EGFR and HER3 would be the main driver of CCL2 produc-
tion. Moreover, the low NF-kB activity in the presence of high
expression of CCL2 as observed in MDAMB453 cells does not
exclude that pathways other than PI3K/AKT may also be
engaged in CCL2 regulation.
The improvement of CCL2 expression observed upon the
degradation of ER by fulvestrant in HER2+/ER+ BC cell lines
in addition to the higher NF-kB activation and expression at
both the mRNA and protein level of CCL2 in HER2+/ER−
compared to HER2+/ER+ BC cell lines support the role of ER
in regulating HER2-driven CCL2 expression, in accordance
with the inhibitory crosstalk between NF-kB and ER
signaling.18 The demonstrated ER involvement in the regula-
tion of CCL2 in HER2+ BC cells is consistent with the
therapeutic activity of trastuzumab mainly in ER− tumors.
Accordingly, NF-kB activation in BCs was found to be nega-
tively associated with ER positivity.18 Specifically, among
HER2+ tumors, only BCs strictly dependent on HER2 (ER−)
showed activation of this pathway, whereas ER+ tumors were
nearly all NF-kB negative.18 Moreover, HER2-E tumors in the
TCGA dataset, which are mainly ER−, exhibit high activation
of the HER2 downstream pathways,23 further supporting
CCL2 regulation by HER2.
The high production of chemokines commonly asso-
ciated with T-cell trafficking (CXCL9, CXCL10, and
CXCL11) by TRAR-low tumor cells also suggests a role
of tumor cells in the recruitment of adaptive immune cells
in the TME. These CXCR3-ligands constitute the major
chemokine axis enabling tumor infiltrating lymphocyte
(TIL) entry into tumors,24 and have been associated with
TIL infiltration in several tumor models.25 Moreover,
increased CCL2 can also trigger T-cell recruitment
through the macrophage ability to engulf and present
antigens using MHC molecules, especially in the presence
of trastuzumab by boosting antibody-dependent cellular
phagocytosis-mediated killing of cancer cells.19
Subsequently, the IFN-γ produced by recruited stimulated
lymphocytes, which has been described to be crucial for
Th1 immunity and trastuzumab response,26 would in turn
induce CXCLs in tumor cells followed by improved T cell-
trafficking and maintenance of immune-enriched TME.
Although tumor antigenicity derived from a high muta-
tional burden, as demonstrated in patients with melanoma
and lung cancer who respond to immune-checkpoint
inhibitors,27-29 may also explain the infiltration of HER2
+ BCs by adaptive immune cells, the low mutational bur-
den of BCs compared to melanoma30 and the lack of
association between the amount of neoantigens and TIL
count or trastuzumab activity in tumors from patients
enrolled in the FinHer trial31 do not support this possibi-
lity. Considering that CXCLs and HER2 mRNA levels are
significantly positively correlated in HER2+ BC samples
and in our in vitro models, it could be hypothesized that
these molecules are co-regulated in trastuzumab respon-
sive HER2-addicted tumors, the subgroup with the highest
HER2 transcription.8 Moreover, as tumor cells have been
shown to acquire the ability to produce growth-promoting
chemokines and to express chemokine receptors,32 it is
likely that high proliferating tumors, such as those
addicted to HER2 signaling, may maintain their own
growth in response to chemokine production. Thus, over-
all, chemokine expression by tumor cells appears to sup-
port the role of HER2 in the maintenance of a “hot
immune” TME.
Irrespective of the recruiting mechanism, TRAR-low
tumors contain a high number of T-cells likely to be
specific for tumor-associated antigens, as indicated by
clonal analyses and tetramer staining of CD8+ T cells
isolated from human tumors.33 The concomitant high
expression of PD-1 ligands in these tumors, as supported
by in situ evaluation of their expression in tumor speci-
mens of HER2+ BCs that showed higher PD-L1 and PD-
L2 positivity in TRAR-low compared to TRAR-high
tumors, may represent one of the mechanisms exploited
by tumors cells to evade immune control. Unlike the
situation in patients with melanoma, in whom PD-L1
expression was described as being a negative feedback
mechanism that followed CD8+ T cell infiltration and
depended on their presence34,35 the modulation of PD-1
ligands by HER2 signals that we demonstrated in BC cell
lines suggests that in HER2+ BCs this immunosuppressive
pathway is also directly orchestrated by cancer cells (i.e.,
innate immune evasion). Thus, the activity of trastuzumab
in therapy-responsive tumors presumably relies on the
antibody’s ability to relieve the suppression of recruited
antitumor effector immunity. This speculation also implies
that the combination of trastuzumab with immune check-
point inhibitors would not be necessary in TRAR-low
tumors, whereas it may represent a valuable strategy for
non-responsive tumors. From a biological perspective, the
direct shaping of the tumor immune milieu by HER2 that
we observed potentially explains the reported ability of
tumor addiction to HER2 as well as of immune infiltrating
cells to predict disease outcome in trastuzumab-treated
patients. The capability of HER2 to fashion an immune
TME would also explain why the immune infiltration of
the primary tumor is predictive of trastuzumab benefit
even in an adjuvant setting, in which the tumor has been
surgically removed and therapy is directed against micro-
metastatic tumor foci.
Together, the obtained results strongly support a con-
nection between HER2 signaling, chemokine production,
and immune cell infiltration of the TME, thus potentially
explaining that HER2 activity per se is sufficient in realiz-
ing benefit from immune-mediated trastuzumab activity.
Furthermore, the role of ER in inhibiting HER2-driven
recruitment of immune cells mediated by NF-kB activa-
tion, in addition to elucidating the lower response to
trastuzumab of HER2+/ER+ compared to HER2+/ER−
BCs, suggests the relevance of ER in conditioning TME.
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This in turn may represent a starting point for a more
targeted project considering the degradation of ER as a
necessary step to increase the activity of immune-mediated
trastuzumab in low responsive HER2+/ER+ BC patients.
Materials and methods
Patients
BCs of the GHEA cohort were previously described.9 All
procedures were in accordance with the Helsinki Declaration
(World Medical Association, 2013). Tumor specimens used
for research consisted of leftover material of samples collected
during standard surgical and medical approaches at
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
(INT). Aliquots were allocated to this study after approval by
the Independent Ethical Committee of Fondazione
IRCCS-INT.
Cell lines, culture, and treatments
Human breast cancer cell lines SKBr3, BT474, ZR75.30,
MDAMB361, HCC1954, and MDAMB453 (American Type
Culture Collection, ATCC) were used in this study. All cell lines
were grown in a humidified chamber (95% air, 5% CO2) at 37°C
and were authenticated using the short tandem repeat profiling
method in our institute facility. SKBr3, ZR75.30, and HCC1954
were cultured in RPMI 1640 (Euroclone, ECB9006D); BT474,
MDAMB361, and MDAMB453 were cultured in Dulbecco’s
modified Eagle’s medium (Life Technologies, 41965–039). Each
mediumwas supplemented with 10% fetal bovine serum (Thermo
Fisher, 16000–036) and 1 mM L-glutamine (LONZA, BE17-
605E). Cells were starved in serum-free medium (0.1% for
SKBr3 and HCC1954) for 48 h and treated with 20 ng/ml EGF
or HRG (Peprotech) for different time points. We used 10 μg/ml
Trastuzumab, 0.3 μM lapatinib, and 10 μM LY294002 (BioMol,
L7751), UO126 (Sigma-Aldrich, #19147), and BAY 11–7082
(Santa Cruz Biotechnology, SC202490) as described.36 ER activity
was blocked using 100 nM fulvestrant (ICI 182–780, I4409,
Sigma-Aldrich).
RNA extraction and qRT-PCR
Total RNA was extracted from cell lines with QIAzol reagent
(Qiagen, 79306) according to the manufacturer’s instructions.
cDNAs were reversed transcribed from 1 μg of total RNA in a
20-μl volume using a High Capacity RNA to cDNA kit
(Thermo Fisher, P/N 4387406). qRT-PCR was performed
using TaqMan probe-based assays (CXCL9: Hs.00171
065_m1, CXCL10: Hs.01124251_g1, CXCL11: Hs.041876
82_g1, CXCL13: Hs.00757930_m1, CCL2: Hs.00234140_m1,
CCL5: Hs.00982282_m1, CCL22: Hs.01574247_m1; PD-L1:
Hs.01125301_m1, PD-L2: Hs.01057777_m1, ERBB2: Hs0100
7077_m1, PGR: Hs00172183_m1, GAPDH: Hs.02758991_g1)
and the TaqMan Fast Universal PCR Master Mix (P/N
4352042) with the ABI Prism 7900HT sequence detection
system (Thermo Fisher). Relative abundances of transcripts
were calculated by the comparative Ct method using GAPDH
as a reference gene.
Western blotting
Protein fractions were extracted from BC cell lines with
TNTG lysis buffer as described.37 The following primary
antibodies were used: rabbit polyclonal antibodies against
phospho-HER2 (Tyr1248, SC12352), HER3 (SC285), ERα
(SC543) (Santa Cruz Biotechnology), Akt (#9272) and phos-
pho-Akt (Ser473, #4060), NF-kB (#4764) and phospho-NF-kB
(Ser536, #3033), EGFR (#1005), p44/42 MAPK (#9102) and
phospho-p44/42 (Thr202/Tyr204, #9101) (Cell Signaling
Technology); mouse monoclonal antibodies anti-HER2,
clone Ab3 (Calbiochem, OP15); anti-vinculin, clone hVIN-1
(Sigma Aldrich, V9131). Polyclonal anti-rabbit (NA9340V) or
anti–mouse (NA931V) IgG horseradish peroxidase (HRP)
(Amersham GE Healthcare) was used as a secondary anti-
body. Protein expression was normalized to that of vinculin.
Flow cytometry
Direct immunofluorescence (IF) on cells derived from diges-
tion of murine mammary carcinomas with collagenase
(300 U/ml) and hyaluronidase (100 U/ml) (StemCell
Technologies, #07912) was performed as described.38 Cells
were stained with the following antibodies:
CD45APCeFluor780 (30-F11, eBioscience), CD11bPE (MI/
70, BD Bioscience), F4/80PerCpCy5.5 (BM8, eBioscience),
CD3FITC (17A2, Miltenyi Biotec), and CD49bPE (DX5,
Miltenyi Biotec). Purified rat anti-mouse CD16/CD32 mono-
clonal (93, eBioscience) was used to prevent non-specific
binding to mouse Fc receptors. Direct IF on human BC cell
lines to evaluate PD-L1 expression was performed by staining
cells with PE-anti-PD-L1 mouse monoclonal antibodies
(MIH1, eBioscience). Samples were analyzed by gating on
live cells after doublet exclusion using the FACSCanto system
(BD Bioscience) and FlowJo software (Tree Star Inc.).
ELISA assay
Soluble CCL2 was quantified in BC cell supernatants and in
plasma derived from mice using human and mouse DuoSet
ELISA kits, respectively (DY279 and DY479, R&D Systems),
following the manufacturer’s instructions. ELISA detection
was performed using 100 μl of cell culture supernatants and
50 μl of plasma samples.
Migration assay
Total splenocytes from healthy mice were obtained as described38
and subjected to amigration assay for 3 h using a Boyden chamber
with a 3-μm filter (Corning, 3415). Plasma obtained at the end of
the experiment frommice treated or not with anti-CCL2 antibody
were pooled and used as chemoattractant. Cells that had migrated
into the lower chamber were counted.
Luciferase assay
NF-kB luciferase assay was performed using the Nano-Glo®
Dual-Luciferase Reporter Assay (NanoDLR®, N1610) accord-
ing to manufacturer’s instructions. In detail, cells were co-
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transfected using Lipofectamine 3000® (Life Technologies,
L3000-008) with pNL3.2 NF-kB-RE reporter and pGL4.54
control vector (Promega, N111A and E849A). At 24 h after
transfection, luciferase activities were measured in cell lysates
using a GLOMAX 20/20 luminometer (Promega).
Immunohistochemistry (IHC)
IHC was performed on FFPE tissue. Slides were deparaffi-
nized, serially rehydrated, subjected to antigen retrieval at 96°
C for 6 min using 10 mM citrate buffer, pH 6.0, and stained
with primary antibodies. The following antibodies were used:
rabbit polyclonal anti human CXCL9 (1:100, NBPI-31155,
Novus Biologicals), rabbit polyclonal anti human CXCL10
(1:100, ab47045, Abcam), mouse anti human CCL2 (1:1000,
mab2791, R&D Systems) rabbit polyclonal anti mouse CCL2
(1:1000, ab2512, Abcam), rabbit polyclonal anti HER2 (1:100,
AO485, Dako Agilent Technologies), mouse anti human
CD68 (1:100, KP1 clone, NB100-683, Novus Biologicals;
1:50, PGM1 clone, M0876, Dako Agilent Technologies),
mouse anti human CD33 (1:100, CD33-L-CE, Leica
Biosystems), rat anti human FOXP3 (1:20, PCH101 clone,
14–4776-80 eBioscience), rabbit polyclonal anti human PD-
L1 (1:100, ab58810, Abcam), and rabbit polyclonal anti
human PD-L2 (1:400, AP30656PU-N, Acris antibodies). PD-
L2 IHC was performed as described.39 Immunoreactions were
visualized using streptavidin-biotin-peroxidase (Dako Agilent
Technologies, E0432, E0433, P0397) and the DAB
Chromogen System (Dako Agilent Technologies, K3468) fol-
lowed by counterstaining with Carazzi hematoxylin. Positive
tumors contained cell cytoplasmic chemokine staining in at
least 10% of tumor or stromal cells, as described.40 Any PD-L1
and PD-L2 staining in tumor cells was considered positive, as
described.41 The numbers of CD68+, FOXP3+, and CD33
+ cells were counted in three-fields at 40X (CD68) and 20X
magnification. Only CD33+ cells in contact with tumor cells
were counted. Blind-coded sections were scored by two inde-
pendent investigators.
Murine tumor tissues were analyzed for HER2 and CCL2
expression by immunofluorescence. Sample imaging was per-
formed using a Leica TCS-SP8-X confocal laser scanning
microscope. The fluorochrome in the immunofluorescence
analysis was excited by a pulsed super continuum White
Light Laser (470–670 nm; 1 nm tuning step size). In particu-
lar, CCL2 was visualized using an AlexaFluor-488 conjugated
secondary antibody (Thermo Fisher, R37116) excited with a
499 nm-laser line and detected at 504 to 561 nm; HER2 was
used after labeling with a Zenon AlexaFluor-546 rabbit IgG
labeling kit (Thermo Fisher, Z25304) and excited with a
557 nm laser line and detected at 562 to 642 nm; and nuclei
were visualized using DAPI (Thermo Fisher, D3571) excited
with a 405-nm diode laser and detected at 422 to 488 nm. The
images were acquired in the scan format 1024 × 1024 using an
HC PL APO 40X/1.3 CS2 oil immersion objective and a pin-
hole set to 1 Airy unit. The data were analyzed using Leica
LAS-X rel.3.1.1 software (Leica Microsystems GmbH). CCL2
positivity was calculated as the positive area of fixed-size
regions (n = 12) manually selected according to HER2-
positivity.
In vivo experiments
Female FVB mice (6- to 8-weeks old; body weight: 20–25 g;
Charles River) were maintained in laminar-flow rooms at
constant temperature and humidity, with food and water
provided ad libitum. Experimental protocols used for ani-
mal studies were approved by the Ethics Committee for
Animal Experimentation of Fondazione IRCCS-INT in
accordance with institutional guidelines. FVB mice were
injected into the mammary fat pad with 1 × 106 MI6 cells,
a murine mammary breast carcinoma cell line derived from
transgenic mice overexpressing the human d16HER2
isoform.15 When tumors were palpable, mice were rando-
mized into two groups to receive three weekly i.p. injections
of CCL2 blocking antibodies (aCCL2) (200 μg/mouse,
BE0185, BioXCell) or control solution. After two doses of
aCCL2, mice in each group were randomized into two
groups (n = 5/group) to receive biweekly i.p. injections of
5 mg/kg trastuzumab or control solution until the end of
the experiment. Tumors in the control groups received the
diluent NaCl solution (0.9%). Tumors were calibrated twice
weekly and tumor volume was calculated as 0.5 × d12 × d2,
where d1 and d2 represent the smaller and larger diameters,
respectively.
Bioinformatics and statistical analysis
Bioinformatics analyses were performed using the BrB-
ArrayTool (v4 .2 .0 , h t tp : / / l inus .nc i .n ih .gov/BRB-
ArrayTools.html). Cluster analysis was performed using
Cluster 3.0 and visualized with Java TreeView applications.
Analyses were performed on BC of the GHEA cohort
(GSE55348).9 Chemokine expression in patients of the
GHEA dataset was analyzed by calculating the mean of
the normalized expression values of all chemokines of the
dataset (Supplementary Table S1). Genes significantly up-
modulated in human M1 and in M2-polarized
macrophages,42 respectively and genes of the LM22
Cibersort list43 were analyzed as M1 and M2 gene patterns
(Supplementary Table S3) in the GHEA dataset by ssGSEA,
as described.44 ERS score was calculated as described.11
CCL2 expression was analyzed in silico in the GSE70360
public dataset14 with processed data retrieved from the
GEO repository.
Differences between groups were determined using a two-
tailed Student’s t-test. Association among categorical variables
was tested by Fisher’s exact test and correlation between
continuous variable by a Pearson correlation analysis.
Differences were considered significant at p < 0.05. Analyses
were performed using GraphPad Prism 5 (GraphPad
Software).
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